Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Core Insights - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [1][3] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 [1] Company Overview - Keros Therapeutics is recognized for its expertise in the TGF-ß protein family, which regulates growth, repair, and maintenance of various tissues including blood, bone, skeletal muscle, adipose, and heart tissue [3] - The company is developing several product candidates: - Cibotercept (KER-012) for pulmonary arterial hypertension and cardiovascular disorders [3] - KER-065 for neuromuscular diseases [3] - Elritercept (KER-050) for treating low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis [3]